New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that new pre-clinical and clinical data for ibrutinib (IMBRUVICA^®) will be highlighted at the 2015 American Association for Cancer Research (AACR) Annual Meeting to be held April 18 – 22, 2015, in Philadelphia, PA. Several company-sponsored and investigator-initiated abstracts have been accepted for presentation as oral and poster sessions highlighting data in solid tumor and blood cancers. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.

"We are very encouraged by the ibrutinib data we are seeing both as a single agent and as a synergistic combination with other treatment options across solid tumor and new hematologic histologies," said Betty Chang, Ph.D., Head of Research at Pharmacyclics. "Based on the success to date within ibrutinib's approved and investigational uses, we remain committed to exploring the further potential of ibrutinib as a backbone of therapy within the broader oncology and hematology arenas."

A select list of accepted ibrutinib abstracts is included below. A full list of accepted ibrutinib data abstracts is available on the AACR website.

Presentations:

Oral Presentation
Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLL (Abstract CT132)
Clinical Trials Minisymposium. Sunday, April 19 at 3:15 p.m. ET in Room 103
Lead Author: Steven Coutre, Stanford University, Stanford, CA

Poster Presentations

Combining ibrutinib with immune checkpoint blockade to induce therapeutic antitumor immune response in solid tumors (Abstract 251; Poster 9)
Immune Checkpoints. Sunday, April 19, 2015 at 1:00 - 5:00 p.m. ET in Section 12
Lead Author: Idit Sagiv-Barfi, Stanford University, Stanford, CA

Ibrutinib enhances the anti-tumor efficacy of CTLA-4 blockade in lymphoma and colon cancer models (Abstract 259; Poster 17)
Immune Checkpoints. Sunday, April 19, 2015 at 1:00 - 5:00 p.m. ET in Section 12
Lead Author: Patrick Ng, Pharmacyclics, Inc., Sunnyvale, CA

Ibrutinib exerts potent antifibrotic activity in a mouse model of pancreatic adenocarcinoma (Abstract 396; Poster 5)
Crosstalk of the Microenvironment and the Tumor Clone. Sunday, April 19, 2015 at 1:00 - 5:00 p.m. ET in Section 17
Lead Author: Daniel Masso-Valles, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Ibrutinib plus proteasome or MALT1 inhibitors overcome resistance to BCR antagonists in CARD11 mutant-expressing B-lymphoma cells (Abstract 1742; Poster 15)
Inhibitors of UPS and HSP90 Pathways and Other Targets. Monday, April 20, 2015 at 8:00 a.m. - 12:00 p.m. ET in Section 31
Lead Author: Ling Xue, Pharmacyclics, Inc, Sunnyvale, CA

Ibrutinib significantly improves survival in a human Burkitt lymphoma (BL) xenograft NSG mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL (Abstract 2608; Poster 30)
MAPK, EGFR, and BTK Inhibitors. Monday, April 20, 2015 at 1:00 - 5:00 p.m. ET in Section 29
Lead Author: Sanghoon Lee, New York Medical College, Valhalla, NY

Synergistic effect of ibrutinib and inhibitors targeting TLR signaling in ABC subtype of diffuse large B-Cell lymphoma (Abstract 2598; Poster 20)
MAPK, EGFR, and BTK Inhibitors. Monday, April 20, 2015 at 1:00 - 5:00 p.m. ET in Section 29
Lead Author: Hsu-Ping Kuo, Pharmacyclics, Inc., Sunnyvale, CA

The BTK inhibitor ibrutinib (PCI-32765) overcomes paclitaxel resistance resulting from the overexpression of ABCB1 and ABCC10 transporters (Abstract 2697; Poster 19)
Resistance to Pathway-Targeted Therapeutics 1. Monday, April 20, 2015 at 1:00 - 5:00 p.m. ET in Section 33
Lead Author: Hui Zhang, Shandong Cancer Hospital and Institute, Jinan, China

Specific antitumor activity of the splicing modulator sudemycin and cooperation with ibrutinib in chronic lymphocytic leukemia (Abstract 2584; Poster 6)
MAPK, EGFR, and BTK Inhibitors. Monday, April 20, 2015 at 1:00 - 5:00 p.m. ET in Section 29
Lead Author: Sílvia Xargay-Torrent, IDIBAPS, Barcelona, Spain